Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers
- PMID: 36620884
- DOI: 10.1158/2159-8290.CD-22-1199
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers
Abstract
In this issue, Hattori and colleagues capitalized on targeted small-molecule covalent inhibitors of one KRAS mutant with a G12C substitution and of other oncoproteins to create drug-peptide conjugates that serve as cancer neoantigens that prompt an immune response to oncogene-mutant cancer cells. This immunotherapy strategy can serve as an effective approach to overcome the treatment-induced resistance that limits the effectiveness of essentially all small molecule-based targeted anticancer drugs. See related article by Hattori et al., p. 132 (9).
©2023 American Association for Cancer Research.
Comment on
-
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy.Cancer Discov. 2023 Jan 9;13(1):132-145. doi: 10.1158/2159-8290.CD-22-1074. Cancer Discov. 2023. PMID: 36250888 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous